Bibliography
- Williams PL, Wu JW, Cohn SE et al.: Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med. 10(5), 29–01 (2009).
- Currier JS, Williams PL, Koletar SL et al.:Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, doubleblind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann. Intern. Med. 133, 493–503 (2000).
- Friis-Moller N, Weber R, Reiss P et al.: Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179–1193 (2003). nn One of the largest cohorts analyzing the effects of antiretroviral therapy on traditional cardiovascular risk factors.
- Purnell JQ, Zambon A, Knopp RH et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14,51–57 (2000).
- Periard D, Telenti A, Sudre P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700–705 (1999).
- van Leth F, Phanuphak P, Stroes E et al.: Nevirapine and efavirenz elicit different changes in lipid profiles i antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 1, e19 (2004).
- Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 17, 2479–2486 (2003).